GO
Loading...

Enter multiple symbols separated by commas

Dyax Says Genetic Disease Drug Meets Goals; Shares Surge

Dyax said its product candidate for hereditary angioedema, a genetic disease, met its main goal in a late-stage trial, sending the biopharmaceutical company's shares up more than 40% in after-hours trading.

The drug, codenamed DX-88, achieved statistically significant results for both the primary and secondary endpoints, Dyax said in a statement.

Hereditary angioedema is characterized by episodes of acute swelling and inflammation.

The company said the overall safety results showed that the drug continues to be well tolerated.

Dyax said it will present more detailed results next week.

Shares of the company rose to $5.87 in late electronic trading, after closing at $4.00 Thursday on the Nasdaq.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • The week ahead: Lunch with Buffett

    CNBC's Kate Rogers looks ahead to what are likely to be next week's top business and financial stories. OPEC meets in Vienna, earnings from Dollar General and Metronic, among others, and investors bid for lunch with Warren Buffett.

  • The week that was: Soccer's super scandal

    CNBC's Kate Rogers looks back at the week's top business and financial stories. Charter announced it would buy Time Warner Cable. And a number of FIFA officials were indicted for receiving $150 million in bribes.

  • Main Street strategies

    Discussing their top investments right now, with Julie Werner, BetterInvesting; Thomas Vitkowski, Cambridge Unversity Press; and Justin Esgar, app developer.